Ankur Banerjee
About Ankur Banerjee
Ankur Banerjee serves as the Editor in Charge of Health and Pharma at Thomson Reuters, focusing on medical technologies and treatments. With a decade of experience in this role, he leads a team that reports on the U.S. biotech sector and manages new reporters.
Work at Thomson Reuters
Ankur Banerjee has been serving as the Editor-in-Charge for Health and Pharma at Thomson Reuters since 2014. His role involves identifying sector-wide trends and writing about new medical technologies and treatments. He contributes to Reuters Health stories, specifically aimed at medical professionals. Prior to his current position, he worked as a Senior Correspondent for Asia Headline News from 2013 to 2014 and as a Correspondent from 2011 to 2013. In these roles, he focused on reporting in the healthcare sector and led a team covering the U.S. biotech sector and M&A activity.
Education and Expertise
Ankur Banerjee completed his Bachelor of Arts in Communication, Journalism, and Related Programs at the Manipal Institute of Communications from 2008 to 2011. His educational background has equipped him with the skills necessary for a successful career in journalism, particularly in the health and pharmaceutical sectors. He also attended Abhinav Bharati High School from 2006 to 2008, where he laid the foundation for his academic pursuits.
Background
Ankur Banerjee began his career in journalism with an internship at the Indian Express in 2010. Following this experience, he joined Thomson Reuters, where he has held various positions over the years. His journey in the organization reflects a steady progression from Correspondent to Senior Correspondent, and ultimately to Editor-in-Charge. His work primarily focuses on the health and pharmaceutical industries, showcasing his commitment to this field.
Achievements
In his current role at Thomson Reuters, Ankur Banerjee has taken on significant responsibilities, including recruiting, mentoring, and managing new team members. He plays a crucial role in shaping them into effective reporters. His leadership in covering the U.S. biotech sector and M&A activity in healthcare demonstrates his expertise and influence in the industry.